Pediatric non-Hodgkin’s lymphoma
- Thomas G. GrossAffiliated withDepartment of Pediatrics, The Ohio State University School of Medicine, Division of Hematology/Oncology/BMT, Children’s Hospital Email author
- , Amanda M. Termuhlen
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Non-Hodgkin’s lymphoma (NHL) accounts for 7% of cancer in children and adolescents in the United States, or approximately 1000 cases annually. NHL in the pediatric population differs from that observed in adult patients with respect to staging systems, histologic subtypes of disease, treatment, and outcomes. Although more than 90% of pediatric NHL is of high-grade histology, more than 80% of patients achieve long-term event-free survival with modern therapy. This review focuses on current treatments for pediatric NHL and some of the differences between NHL observed in pediatric and adult patients.
- Pediatric non-Hodgkin’s lymphoma
Current Oncology Reports
Volume 9, Issue 6 , pp 459-465
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links